139 related articles for article (PubMed ID: 22772533)
1. First therapy targeting Parkinson's proteins enters clinical trials.
Dolgin E
Nat Med; 2012 Jul; 18(7):992-3. PubMed ID: 22772533
[No Abstract] [Full Text] [Related]
2. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.
Volc D; Poewe W; Kutzelnigg A; Lührs P; Thun-Hohenstein C; Schneeberger A; Galabova G; Majbour N; Vaikath N; El-Agnaf O; Winter D; Mihailovska E; Mairhofer A; Schwenke C; Staffler G; Medori R
Lancet Neurol; 2020 Jul; 19(7):591-600. PubMed ID: 32562684
[TBL] [Abstract][Full Text] [Related]
3. T cells from patients with Parkinson's disease recognize α-synuclein peptides.
Sulzer D; Alcalay RN; Garretti F; Cote L; Kanter E; Agin-Liebes J; Liong C; McMurtrey C; Hildebrand WH; Mao X; Dawson VL; Dawson TM; Oseroff C; Pham J; Sidney J; Dillon MB; Carpenter C; Weiskopf D; Phillips E; Mallal S; Peters B; Frazier A; Lindestam Arlehamn CS; Sette A
Nature; 2017 Jun; 546(7660):656-661. PubMed ID: 28636593
[TBL] [Abstract][Full Text] [Related]
4. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles.
Doucet M; El-Turabi A; Zabel F; Hunn BHM; Bengoa-Vergniory N; Cioroch M; Ramm M; Smith AM; Gomes AC; Cabral de Miranda G; Wade-Martins R; Bachmann MF
PLoS One; 2017; 12(8):e0181844. PubMed ID: 28797124
[TBL] [Abstract][Full Text] [Related]
5. Immunologic treatment of Parkinson's disease.
Jankovic J
Immunotherapy; 2018 Feb; 10(2):81-84. PubMed ID: 29260621
[No Abstract] [Full Text] [Related]
6. Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.
Shahaduzzaman M; Nash K; Hudson C; Sharif M; Grimmig B; Lin X; Bai G; Liu H; Ugen KE; Cao C; Bickford PC
PLoS One; 2015; 10(2):e0116841. PubMed ID: 25658425
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
[TBL] [Abstract][Full Text] [Related]
8. Roles for the adaptive immune system in Parkinson's and Alzheimer's diseases.
Lindestam Arlehamn CS; Garretti F; Sulzer D; Sette A
Curr Opin Immunol; 2019 Aug; 59():115-120. PubMed ID: 31430650
[TBL] [Abstract][Full Text] [Related]
9. Autoimmunity in Parkinson's Disease: The Role of α-Synuclein-Specific T Cells.
Garretti F; Agalliu D; Lindestam Arlehamn CS; Sette A; Sulzer D
Front Immunol; 2019; 10():303. PubMed ID: 30858851
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule inhibitors of α-synuclein for the treatment of Parkinson's disease: a patent landscape.
Joubert J
Pharm Pat Anal; 2020 May; 9(3):63-65. PubMed ID: 32602809
[No Abstract] [Full Text] [Related]
11. Sticking it to Parkinson's disease.
Leslie M
Sci Aging Knowledge Environ; 2005 Jun; 2005(25):nf46. PubMed ID: 15975896
[No Abstract] [Full Text] [Related]
12. CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease.
Williams GP; Schonhoff AM; Jurkuvenaite A; Gallups NJ; Standaert DG; Harms AS
Brain; 2021 Aug; 144(7):2047-2059. PubMed ID: 33704423
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.
Brys M; Fanning L; Hung S; Ellenbogen A; Penner N; Yang M; Welch M; Koenig E; David E; Fox T; Makh S; Aldred J; Goodman I; Pepinsky B; Liu Y; Graham D; Weihofen A; Cedarbaum JM
Mov Disord; 2019 Aug; 34(8):1154-1163. PubMed ID: 31211448
[TBL] [Abstract][Full Text] [Related]
14. Antibodies against alpha-synuclein: tools and therapies.
Vaikath NN; Hmila I; Gupta V; Erskine D; Ingelsson M; El-Agnaf OMA
J Neurochem; 2019 Sep; 150(5):612-625. PubMed ID: 31055836
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease.
Olson KE; Gendelman HE
Curr Opin Pharmacol; 2016 Feb; 26():87-95. PubMed ID: 26571205
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders.
Neff F; Wei X; Nölker C; Bacher M; Du Y; Dodel R
Autoimmun Rev; 2008 Jun; 7(6):501-7. PubMed ID: 18558370
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
George S; Brundin P
J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
[TBL] [Abstract][Full Text] [Related]
18. Intrabody and Parkinson's disease.
Zhou C; Przedborski S
Biochim Biophys Acta; 2009 Jul; 1792(7):634-42. PubMed ID: 18834937
[TBL] [Abstract][Full Text] [Related]
19. Homologous HSV1 and alpha-synuclein peptides stimulate a T cell response in Parkinson's disease.
Caggiu E; Paulus K; Galleri G; Arru G; Manetti R; Sechi GP; Sechi LA
J Neuroimmunol; 2017 Sep; 310():26-31. PubMed ID: 28778441
[TBL] [Abstract][Full Text] [Related]
20. The Library Derived 4554W Peptide Inhibits Primary Nucleation of α-Synuclein.
Meade RM; Morris KJ; Watt KJC; Williams RJ; Mason JM
J Mol Biol; 2020 Dec; 432(24):166706. PubMed ID: 33186583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]